The next generation of immunotherapy targets a $60 billion market with non-small cell lung cancer as the biggest opportunity.

Excel analysis shows that in 2024, out of the global sales of 49 billion dollars for the top five immune checkpoint inhibitors, non-small cell lung cancer accounts for 40%, highlighting why novel bispecific antibodies are targeting this market. It is anticipated that by 2027, this market will experience strong growth, with global sales peaking at over 60 billion dollars, after which pricing pressure from the "Inflation Reduction Act" and patent expirations will begin to suppress the market. In order to support premium pricing, new therapies need to demonstrate significant clinical benefits. BioNTech is leading the expansion into areas beyond non-small cell lung cancer, planning to conduct registration trials in breast cancer and small cell lung cancer. Summit may next target gastrointestinal tumors and provide adjuvant therapy for non-small cell lung cancer.